Generics Bulletin
Samsung Bioepis Pushes Stelara Rival Into Phase I
By David Wallace 01 Mar 2021
Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase...
Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.
Your free article pack from Generics Bulletin includes intelligence spanning a wide array of industry developments. Articles include:
Launches:
“Teva Sticks With 10% Discount For Trastuzumab”
Strategy:
“Stada Says Teriparatide Roll-Out Has Been Successful”
Product development:
“Revance Awaits Mylan Decision On Botox Biosimilar”
And many more
Your free article pack from Generics Bulletin includes intelligence spanning a wide array of industry developments. Articles include:
Regulations:
“FDA Overhauls Its Purple Book”
Litigation and Intellectual Property:
“Amgen Cleared Again On Kanjinti As Trial Looms”
Industry Interviews:
“Celltrion Healthcare Gears Up For Infliximab SC Launch”
And many more
Generics Bulletin
By David Wallace 01 Mar 2021
Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase...
Generics Bulletin
By David Wallace 01 Mar 2021
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US...
Generics Bulletin
By David Wallace 26 Feb 2021
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: